AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33032795
Drug: Self-regulation programme
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-regulation programme (4-week duration, including one 20-30 min face-to-face education session and 15-20 min telephone follow-ups twice per week)
Trial: 33787192
Drug: Zingiber officinale
RxNorm normalized name: Zingiber officinale oil
DrugBank: Ginger oil (DB14690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zingiber officinale (Tablet Vomigone 500 mg II tds) and Echinacea (Tablet Rucoldup I tds) for seven days in addition to standard treatment (Hydroxychloroquine)
Trial: 33787192
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Hydroxychloroquine)
Trial: 34378863
Drug: High-dose ergocalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ergocalciferol (double dosage from K/DOQI guidelines) for 8 weeks
Trial: 34378863
Drug: Conventional-dose ergocalciferol
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional-dose ergocalciferol (standard dosage according to K/DOQI guidelines) for 8 weeks
Trial: 34378863
Drug: High-dose ergocalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ergocalciferol (for subgroup with serum 25[OH]D <20 ng/ml)
Trial: 34378863
Drug: Conventional-dose ergocalciferol
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional-dose ergocalciferol (for subgroup with serum 25[OH]D <20 ng/ml)
Trial: 32450709
Drug: X-ray irradiation
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: X-ray irradiation of nitroxyl radical solutions
Trial: 34996424
Drug: Internet-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioral therapy (ICBT) for two menstrual cycles
Trial: 36403542
Drug: Cream with
RxNorm normalized name: CREAM WITH APPLICATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream with nanoparticles containing vitamin E
Trial: 36403542
Drug: Cream without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream without nanoparticles or vitamin E (Control 1)
Trial: 36403542
Drug: Cream with
RxNorm normalized name: CREAM WITH APPLICATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream with nanoparticles without vitamin E (Control 2)
Trial: 35028688
Drug: Vaccinium fruit
RxNorm normalized name: Vaccinium myrtillus fruit
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinium fruit supplements
Trial: 36460535
Drug: FD MVA-BN
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FD MVA-BN vaccine (3 lots)
Trial: 33650407
Drug: Aviron Rapid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aviron Rapid® + standard symptomatic therapy
Trial: 33650407
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + standard symptomatic therapy
Trial: 34426507
Drug: Plasma adiponectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma adiponectin levels of 19.2 μg/mL (3rd quartile)
Trial: 34426507
Drug: Plasma adiponectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma adiponectin levels of 13.9 μg/mL (2nd quartile)
Trial: 34426507
Drug: Plasma adiponectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma adiponectin levels of 9.2 μg/mL (1st quartile)
Trial: 34426507
Drug: 1 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg/mL lower plasma adiponectin
Trial: 32580987
Drug: Intrapartum antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapartum antibiotics
Trial: 32932482
Drug: Randomization of
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization of pixel positions in hologram display using a liquid crystal modulator
Trial: 33998882
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) chewing gum (50 mg)
Trial: 38092285
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing plus cognitive behavioral therapy
Trial: 35420695
Drug: Stereotactic adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic adjuvant pelvic radiation to a dose of 30 Gy in 5 fractions administered every other day or once weekly
Trial: 33649979
Drug: Higher dosing
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dosing regimen (> 4000 IU)
Trial: 34912512
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 (80 mg)
Trial: 36463724
Drug: GRASP (GRoup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRASP (GRoup trAining for Social skills in Psychosis) plus treatment-as-usual (TAU)
Trial: 33875426
Drug: Clofazimine 300
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine 300 mg daily for 3 days, followed by 100 mg daily for 11 days
Trial: 33875426
Drug: Clofazimine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofazimine (loading doses of 200 and 300 mg)
Trial: 35671089
Drug: Reported daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reported daily use of mobile phones
Trial: 35671089
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment uptake
Trial: 34383903
Drug: Pecan consumption
RxNorm normalized name: Pecan
DrugBank: Pecan (DB10555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pecan consumption (68 g) as part of a free-living diet (ADD group, n = 16)
Trial: 34383903
Drug: Pecan substitution
RxNorm normalized name: Pecan
DrugBank: Pecan (DB10555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pecan substitution (68 g) for isocaloric foods (SUB group, n = 18)
Trial: 34980232
Drug: ANC counseling
RxNorm normalized name: ANC-501
DrugBank: ANC-501 (DB18907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANC counseling plus BEP supplement
Trial: 34980232
Drug: ANC counseling
RxNorm normalized name: ANC-501
DrugBank: ANC-501 (DB18907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANC counseling plus BEP supplement plus 2 doses azithromycin
Trial: 34980232
Drug: ANC counseling
RxNorm normalized name: ANC-501
DrugBank: ANC-501 (DB18907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANC counseling plus BEP supplement plus daily single dose of nicotinamide and choline
Trial: 35321739
Drug: Prediction-aided decisions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction-aided decisions during bDMARD tapering
Trial: 32618436
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with high-risk regimens including cisplatin or carboplatin and doxorubicin (19 patients), or cisplatin or carboplatin alone (3 patients)
Trial: 34544324
Drug: Pregabalin and
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin and exercise therapy
Trial: 35654972
Drug: Liraglutide (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (a GLP‐1 receptor agonist)
Trial: 32767766
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium for oral solution (50 mg)
Trial: 32727733
Drug: 30% fluence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% fluence rate of photodynamic therapy (PDT)
Trial: 32727733
Drug: 40% fluence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% fluence rate of photodynamic therapy (PDT)
Trial: 32727733
Drug: 50% fluence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% fluence rate of photodynamic therapy (PDT)
Trial: 35352703
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy intervention teaching pain self-management skills in 12 weekly, 90-minute groups
Trial: 35352703
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy intervention
Trial: 33972581
Drug: Citric-acid dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citric-acid dialysate (C1.5) with dCa of 1.50 mmol/l
Trial: 33972581
Drug: Acetic-acid dialysate
RxNorm normalized name: Acetic Acid
DrugBank: Acetic acid (DB03166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetic-acid dialysate with dCa of 1.25 mmol/l (A1.25)
Trial: 33972581
Drug: Acetic-acid dialysate
RxNorm normalized name: Acetic Acid
DrugBank: Acetic acid (DB03166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetic-acid dialysate with dCa of 1.50 mmol/l (A1.5)
Trial: 33417730
Drug: Daridorexant 50
RxNorm normalized name: daridorexant 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daridorexant 50 mg once daily for 5 consecutive days
Trial: 36293971
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.3 g/kg body weight)
Trial: 34388379
Drug: Bevacizumab (VEGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (VEGF inhibitor) added to Erlotinib (EGFR inhibitor)
Trial: 34388379
Drug: Erlotinib (EGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (EGFR inhibitor) alone
Trial: 34208829
Drug: Chemical agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical agents acting on RBC membrane channels
Trial: 34208829
Drug: Recombinant Annexin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Annexin V pre-treatment
Trial: 34208829
Drug: Modulators of
RxNorm normalized name: SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modulators of RBC membrane channels (activating Piezo1 Ca2+ channel)
Trial: 34810363
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with education for self‐management and counseling
Trial: 33109641
Drug: IA injection
RxNorm normalized name: factor VIIa Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA injection of HA+CS combined with duloxetine
Trial: 33109641
Drug: IA injection
RxNorm normalized name: factor VIIa Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA injection of HA+CS alone
Trial: 35030257
Drug: Escalated antiarrhythmic
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated antiarrhythmic drug therapy (specifically amiodarone)
Trial: 34160595
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus psychosocial treatment
Trial: 34160595
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication plus psychosocial treatment
Trial: 35058236
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg CC-90001
Trial: 35058236
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg CC-90001
Trial: 35058236
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg CC-90001 (PF-ILD substudy)
Trial: 32998924
Drug: Topical natamycin
RxNorm normalized name: Natamycin
DrugBank: Natamycin (DB00826)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical natamycin 5%
Trial: 33045374
Drug: 10% daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% daily contrast increment protocol
Trial: 33045374
Drug: 5% daily
RxNorm normalized name: NaFrinse 0.05% Daily Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% daily contrast increment protocol
Trial: 33045374
Drug: 0% daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0% daily contrast increment protocol
Trial: 32803888
Drug: Lindera strychnifolia
RxNorm normalized name: Lindera aggregata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lindera strychnifolia root extract (LsR) treatment for 83 days
Trial: 32803888
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (AGA subjects without treatment)
Trial: 36081953
Drug: QL1209 420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL1209 420 mg intravenously
Trial: 36081953
Drug: Perjeta® 420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perjeta® 420 mg intravenously
Trial: 34228875
Drug: 10-mg oral
RxNorm normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-mg oral solution oxycodone
Trial: 34228875
Drug: 20-mg controlled-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg controlled-release (water-swellable or lipid-based) oxycodone
Trial: 32092187
Drug: LCP‐tac and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCP‐tac and everolimus once daily
Trial: 35835346
Drug: Ward-based goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ward-based goal-directed fluid therapy (GDFT)
Trial: 34520293
Drug: Existing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing treatment comparison tests under non-proportional hazards
Trial: 35638455
Drug: 30% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% NaCl solution
Trial: 36088270
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ibuprofen (10mg/kg/6h)
Trial: 36088270
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac (0.5mg/kg/6h)
Trial: 32147962
Drug: Cash transfers
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cash transfers and monthly group nutrition education sessions led by community health volunteers
Trial: 33836388
Drug: Topical ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketamine cream 10%
Trial: 33836388
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 g of cold cream)
Trial: 33508845
Drug: Predialytic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predialytic oral nutritional supplements (ONS) (450 kcal energy, 20 g protein) administered 1 hour prior to dialysis
Trial: 33508845
Drug: Intradialytic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradialytic oral nutritional supplements (ONS) (450 kcal energy, 20 g protein) administered after 2 hours of dialysis
Trial: 35172685
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin plus chemotherapy (A + CHP)
Trial: 34514706
Drug: Solution-Focused Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-Focused Support Program (SFSP), 4 sessions of online support, 1 session per week
Trial: 32169003
Drug: Support group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Support group for typically developing siblings; details on dosage and duration not available.
Trial: 32169003
Drug: Similar group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar group without a focus on the sibling with autism spectrum disorder; details on dosage and duration not available.
Trial: 32116139
Drug: Artificial food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial food coloring (AFC) 225 mg in chocolate cookies for 3 days
Trial: 33964196
Drug: Epidural solution
RxNorm normalized name: Lidocaine Hydrochloride 1% Epidural Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural solution of bupivacaine 1 mg mL-1, fentanyl 2 μg mL-1 with adrenaline 2 μg mL-1
Trial: 33964196
Drug: Epidural solution
RxNorm normalized name: Lidocaine Hydrochloride 1% Epidural Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural solution of bupivacaine 1 mg mL-1, fentanyl 2 μg mL-1 without adrenaline
Trial: 35674835
Drug: Ticagrelor (180-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180-mg loading dose)
Trial: 35674835
Drug: Clopidogrel (600-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600-mg loading dose)
Trial: 35148516
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg oral tamsulosin for 5 days preoperatively and 2 days postoperatively
Trial: 32041658
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide 4-6 µg/kg
Trial: 32041658
Drug: Glycopyrronium bromide
RxNorm normalized name: Glycopyrronium bromide
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glycopyrronium bromide 4 µg/kg (active placebo)
Trial: 35971150
Drug: e‐cigarettes with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e‐cigarettes with 18 mg/ml nicotine
Trial: 39423145
Drug: Deucravacitinib 12
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib 12 mg
Trial: 35182043
Drug: Deucravacitinib 36
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib 36 mg
Trial: 33118927
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBTi), n = 72
Trial: 33118927
Drug: No-treatment control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control, n = 73
Trial: 35671086
Drug: NRD.E1 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRD.E1 at 40 mg/day
Trial: 35671086
Drug: NRD.E1 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRD.E1 at 150 mg/day
Trial: 33548056
Drug: Social support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social support pre-treatment
Trial: 36309984
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with Simvastatin and Ezetimibe
Trial: 33649098
Drug: Rituximab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1 g) on days 1 and 15
Trial: 33389614
Drug: Combined mammography
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined mammography and adjunctive ultrasound
Trial: 35517806
Drug: Crocin supplementation
RxNorm normalized name: crocin
DrugBank: Crocin (DB11874)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocin supplementation (30 mg/day for 12 weeks)
Trial: 34991056
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) at 10-30 mg/kg/day
Trial: 34991056
Drug: Placebo (previous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (previous treatment)
Trial: 33512065
Drug: KHK4083 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHK4083 (10 mg/kg, single intravenous dose)
Trial: 33512065
Drug: KHK4083 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHK4083 (multiple intravenous doses)
Trial: 36346336
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health promotion management
Trial: 33767376
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein regimen (18% energy intake as amino acids, targeting 4 g/kg/day)
Trial: 33767376
Drug: Conventional regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional regimen (12.5% energy intake as amino acids, targeting 3 g/kg/day)
Trial: 34461161
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral thiamine (one gram twice daily)
Trial: 34729774
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus the interprofessional student-run medication review program (ISP)
Trial: 34488269
Drug: Narrative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative therapy (once a week for 30 min over 6 weeks)
Trial: 34488269
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine clinical treatment)
Trial: 35166608
Drug: Physiotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy treatment plus virtual reality exercises with the Nintendo Wii console (n=36)
Trial: 35166608
Drug: Physiotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy treatment (control group, n=37)
Trial: 33588078
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (2000 IU daily)